In Silico Characterization of Bromo-DragonFLY Binding to the 5-HT_2A Receptor: Molecular Insights Into a Potent...

Bromo-DragonFLY (BDF), a potent designer psychedelic drug with hallucinogenic properties, has recently emerged as a significant recreational substance. Named for its dragonfly-like molecular structure, BDF induces prolonged psychedelic effects, with hallucinations lasting several days. Clinical reports highlight severe toxicity, including confusion, tachycardia, hypertension, seizures, renal failure, and, in extreme cases, death. BDF acts as a potent agonist of the 5-HT2A serotonin receptor subtype, which mediates the behavioral and psychedelic effects of hallucinogens. Despite its increasing prevalence and associated clinical implications, the precise molecular mechanisms underlying BDF's interaction with 5-HT2A remain inadequately characterized, particularly from an in silico perspective. This study addresses this gap by employing a comprehensive in silico framework to investigate the molecular interactions of BDF with the 5-HT_2A receptor. Molecular docking was used to identify binding sites, while all-atom molecular dynamics (MD) simulations provided insights into the stability of the protein-ligand complex, assessing deviations, local flexibility, and time-dependent gyration patterns. The results revealed stable and compact complex formation between BDF and 5-HT_2A, characterized by minimal per-residue fluctuations and high hydrogen bond occupancy, suggesting a highly stable interaction as shown experimentally. Additionally, principal component analysis, leveraging machine learning algorithms, demonstrated consistent motion, while free energy profiles highlighted stable energy basins with minimal variations for the BDF-5-HT_2A complex. These findings suggest strong binding affinities of BDF with the serotonin receptor, leading to highly stable complex formation. This study provides a foundational understanding of BDF's molecular interactions, offering critical insights into its role as a potent psychedelic agent and laying the groundwork for future investigations into the risks posed by novel designer drugs.